January 04, 2019
Rose
In the first major pharmaceutical deal of 2019, Bristol-Myers Squibb says it will buy Celgene, a maker of cancer-fighting drugs, in a merger valued at $74 billion. According to Stat, Bristol-Myers has been under pressure to set a new course since August 2016, when a big study of its cancer immunotherapy, Opdivo, failed to show a benefit in previously untreated patients with non-small cell lung cancer. Analysts look at what the deal means to the industry at large.
from Kaiser Health News http://bit.ly/2VxhSnI
January 04, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Different Takes: Medicaid Work Requirements Grant States ‘Flexibility’; The Able-Bodied Are ‘Everywhere’- State Highlights: Iowa’s Bill To Boost Mental Health Care Expected; Community Health Centers In Conn. Get Temporary Funding
- Senators Hope To Hammer Out A Deal With White House On VA Choice Program
- Viewpoints: Will Trump Keep Promise To Tackle Opioid Crisis? ‘Right To Try’ Law Is Right For Patients
- Worried About Brain Impact Of Tech? So Are Some Early Facebook, Google Employees Who Are Teaming Up
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment